Mito-LND - 10mM in DMSO , CAS No.2361564-49-8

CAS: 2361564-49-8 Cat. No.: M654885 Summenformel: C₄₃H₄₅BrCl₂N₃OP Molekulargewicht: 801.62 PubChem CID: 155977659

GRADE & PURITY 10mM in DMSO

Storage

Desiccated,Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species , and induces autophagic cell death in lung cancer cells.

In Vitro

Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC 50 values of 0.74 µM and 0.69 µM, respectively. Mito-LND inhibits mitochondrial complex I and II activities with IC 50 values of 1.2 µM and 2.4 µM, respectively in H2030BrM3 cells. Mito-LND (1 µM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells. Mito-LND (2 µM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mito-LND (7.5 µmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis . Mito-LND also decreases the rate of growth of A549 tumor xenografts . Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Athymic nude mice (5 weeks) injected with H2030BrM3 cells Dosage: 7.5 µmol/kg Administration: Oral gavage; 5 days per week; for 3 consecutive weeks Result: Significantly decreased tumor progression.

Specifications

Spezifikationen & Reinheit

10mM in DMSO

Biochemische und physiologische Mechanismen

Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS) . Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species , and induces autophagic cell dea

Storage

Desiccated,Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Namen und Kennungen

• Isomere SMILES: C1=CC=C(C=C1)[P+](CCCCCCCCCCNC(=O)C2=NN(C3=CC=CC=C32)CC4=C(C=C(C=C4)Cl)Cl)(C5=CC=CC=C5)C6=CC=CC=C6.[Br-]
• PubChem CID: 155977659
• Molekulargewicht: 801.62

Häufig gestellte Fragen

How should this product be stored?

Store at ?80 °C, desiccated. Keep the container tightly closed with desiccant — the material is moisture-sensitive.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2361564-49-8, the molecular formula is C43H45BrCl2N3OP, and the molecular weight is 801.62 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.